ASPAVELI 1 080 mg solution for infusion
Sponsors
Apellis Pharmaceuticals Inc.
Conditions
C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)Paroxysmal Nocturnal Hemoglobinuriacomplement 3 glomerulopathy (C3G)/immune complex
membranoproliferative glomerulonephritis (IC-MPGN)complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Phase 2
An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria
RecruitingCTIS2024-516350-22-00
Start: 2021-10-22Target: 4Updated: 2024-12-16
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN
CompletedCTIS2024-511544-36-00
Start: 2021-12-21End: 2025-11-24Target: 7Updated: 2024-12-04
Phase 3
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)
Active, not recruitingCTIS2023-504625-39-00
Start: 2023-05-18Target: 66Updated: 2026-01-08
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
CompletedCTIS2024-514130-20-00
Start: 2022-04-04End: 2024-12-09Target: 19Updated: 2024-11-26